 |
|
 |
 |

Home > Company Index > Drugs > Diagnostic Substances > Matritech, Inc.
 |
Matritech, Inc. |
 |
 |
 |
PROFILE |
 |
Matritech hopes to be the matriarch of cancer-detection products. The biomedical company develops diagnostic tests for different types of cancer. Its proprietary nuclear matrix protein (NMP) technology (licensed from MIT) tests blood, cell, and urine samples to detect and monitor differences in healthy cells and cancerous cells; such analyses offer an alternative to painful instrument-based exams. Matritech has an agreement with a division of Fisher Healthcare Company to distribute bladder cancer test NMP22, its first product, in the US; the test is also sold in select Asian and European countries. Matritech is developing other diagnostics for cervical, breast, and prostate cancer.
COMPETITION |
 |
DIANON Systems, Inc. (DIAN)
UroCor, Inc. (UCOR)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.20
1-Yr. Sales Growth: 100.0%
Employees: 42
Revenue per employee: $28,571.43
KEY PEOPLE |
 |
Stephen D. Chubb
CEO
John S. Doherty
CFO
CONTACT INFO |
 |
330 Nevada St.
Newton, MA 02460
US
Phone: 617-928-0820
Fax: 617-928-0821
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |